索拉非尼埃及获批 科兴制药MENA地区商业化添关键成果

Group 1 - The core viewpoint of the news is that Kexing Pharmaceutical has successfully commercialized its product, tolvaptan, in the overseas market, specifically receiving approval from the Egyptian Drug Authority for its marketing [1] - The global market size for sorafenib, a well-known targeted therapy drug, reached 4.889 billion RMB in 2023, indicating significant market potential [1] - Egypt's pharmaceutical market is expected to grow from 152.8 billion EGP (approximately 3 billion USD) in 2024 to 218.1 billion EGP (approximately 4.3 billion USD) by 2028, with a compound annual growth rate of 9.6% [2] Group 2 - Kexing Pharmaceutical has established a subsidiary in Egypt and is focusing on localized operations, which includes the introduction of foreign talent and the registration of key products like bevacizumab and infliximab [3] - The company has introduced nearly 20 overseas commercialized products, and with the successful launch of several major products, its long-term value as a multinational pharmaceutical company is expected to emerge [3] - The collaboration with Beijing Yabao Biological Pharmaceutical Co., Ltd. for the overseas commercialization of tolvaptan has led to significant progress in registration across multiple countries, enhancing the accessibility of this cancer treatment [2][3]